(Q52855355)

8 May 2018

title

Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment? (English)

1 reference

8 May 2018

2

Paul Emery

1 reference

8 May 2018

Maya Hema Buch

series ordinal

1

object named as

Maya H Buch

1 reference

8 May 2018

publication date

1 June 2006

1 reference

8 May 2018

Nature Clinical Practice Rheumatology

published in

1 reference

8 May 2018

volume

2

1 reference

8 May 2018

issue

6

1 reference

8 May 2018

page(s)

288-289

1 reference

8 May 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0210

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0210

1 reference

8 May 2018

1 reference

8 May 2018